the future of
bleeding
control
is Now

At Medcura, our breakthrough biopolymer technologies are
redefining hemostasis with solutions designed to address
real problems — for patients, surgeons, and payers.

At Medcura, our breakthrough biopolymer technologies are redefining hemostasis with solutions designed to address real problems — for patients, surgeons, and payers.

Disruptive Surgical technology platform

Our novel hemostasis portfolio of products is created from natural, hydrophobically modified biomaterials designed to stop minimal, mild and moderate surgical bleeding. Medcura products achieve hemostasis by mechanical means, coating the bleeding site via the process of mucoadhesion.

Medcura’s proprietary biomaterial platform is engineered to provide safe, effective, and lower cost bleeding management solutions*,** — with the potential to pass savings from the manufacturer to providers with cost-effective and strategic-purchasing opportunities.

Universally affordable

Dig deeper into the science to understand how to optimize bleeding control and patient care at a lower cost to providers and payers.

Learn More

the new backbone for spine surgery and the $2.5B hemostasis market1

FDA Breakthrough Device Designation: for surgical procedures where swelling cannot be tolerated. 2

Current and popular hemostatic flowable technologies swell.3-10 For complex medical procedures, hemostatic agent swelling can cause nerve injury and even paralysis when used in confined areas.5

For highly specialized surgical procedures like surgeries of the spine, Medcura's LifeGel™ is the first and only flowable hemostatic gel designed to address challenges specific to hemostatic swelling—effectively reducing the risk of major adverse events like nerve injury and paralysis, especially when used in confined spaces, which can be caused by hemostatic agent swelling during spine surgery.6  LifeGel is under active development.

Explore LifeGel™
“With the experience we've gained through extensive pre-clinical testing, LifeGel has shown to be easy and intuitive to use, while demonstrating a remarkable ability to control a wide range of challenging bleeding situations."

Dr. Ken Renkens

Retired Spine Surgeon / Medcura Chief Medical Officer

For Investors

Explore the Medcura product pipeline, vision for the future, and partnership opportunities.

Learn More

In The News

April 3, 2024
Medcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis Portfolio

Medcura Closes $22.4 Million Financing to Accelerate Development of Surgical Hemostatic Gel and Surgical Hemostasis Portfolio

September 10, 2024
Why Medcura’s LifeGel™ Is the Backbone of a Surgery Revolution

Why Medcura’s LifeGel™ Is the Backbone of a Surgery Revolution

September 25, 2024
Medcura's Hemostatic Agent LifeGel™ Wins 2024 Spine Technology Award

Medcura's Hemostatic Agent LifeGel™ Wins 2024 Spine Technology Award

See all News

Meet The Team

Get to know the team of scientists, engineers, translational and clinical researchers, surgeons, and medical device experts at Medcura.

More About Medcura

Jim Buck

President, CEO & Director

Join Us

Are you interested in learning how to invest? A surgeon interested in participating in a clinical study? A distributor interested in carrying the Medcura portfolio of surgical solutions? Enter your email address below and we'll be in touch.

By clicking Sign Up you're confirming that you agree with our Terms of Use.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Disclaimer

LifeGel and its application tips are currently in development. All intended uses and/or indications for use for this medical device and its application tips have not been cleared or approved by the FDA.

References

*  Data on file at Medcura. Ongoing exploratory/development testing for safety and  performance.

** Data on file at Medcura. Ongoing research for time and cost efficiencies.

  1. DRG/Clarivate US Biosurgery Insights, 2021 
  2. https://www.fdanews.com/articles/210821-medcura-receives-breakthrough-device-designation-for-lifegel-to-manage-surgical-bleeding?v=preview
  3. Arista ® AH Absorbable Hemostatic Particles, Instructions for Use,; Warnings. Davol Inc. Subsidiary of C. R. Bard, Inc., Warwick, RI; 2015, Arista-AH
  4. GelFoam ® absorbable gelatin compressed sponge, USP, Instructions for Use; Warnings. Pfizer, Pharmacia & Upjohn Company LLC, New York, NY; 05/2022
  5. GelFoam ® absorbable gelatin powder from absorbable gelatin sponge, USP, Instructions for Use; Warnings. Pfizer, Pharmacia & Upjohn Company LLC, New York, NY; 05/2022,
  6. PerClot ® Polysaccharide Hemostatic System, Instructions for Use, Warnings. Starch Medical Inc., San Jose, CA, Uploaded 2019, PerClot-IFU
  7. Surgicel ® Powder, Absorbable Hemostatic Powder, Instructions for Use, Contraindications. Ethicon, LLC, San Lorenzo, Puerto Rico; 05/2017
  8. Surgicel ® SNoW Absorbable Hemostatic, Instructions for Use, Contraindications; Adverse Events. Ethicon, LLC, San Lorenzo, Puerto Rico; 05/2013
  9. SurgifloTM Hemostatic Matrix Kit, Essential Product Information, Warnings; Precautions. Ethicon Johnson and Johnson Surgical Technologies; 2022, SURGIFLO-Hemostatic-Matrix-Brochure
  10. SurgicelTM Original/ Surgicel NU-KNIT/ Surgicel Fibrillar Absorbable Hemostats, Instructions for Use, Contraindications; Adverse Events. Ethicon, Neuchâtel, Switzerland; 06/2013

‍